Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hepatitis C

Free Subscription Articles published in Hepatology Retrieve available abstracts of 87 articles: HTML format

Single Articles

July 2024
1. 
   Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
   Hepatology. 2024;80:E21.
   PubMed    
   
   
   June 2024
2. LAW JL, Drummer HE
   Bridging the gap: A new tool to down select HCV vaccine candidates.
   Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000000948.
   PubMed    
   
   
   
3. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
   Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
   Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
   PubMed    
   
   
   
4. HUANG L, Zou L
   Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
   Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
   PubMed    
   
   
   
5. CORNBERG M, Wedemeyer H
   Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination!
   Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958.
   PubMed    
   
   
   May 2024
6. POL S, Thompson AJ, Collins M, Venier E, et al
   Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
   Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
   PubMed     Abstract available
   
   
   
7. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
   The obstacle is the way: Finding a path to hepatitis C elimination.
   Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
   PubMed    
   
   
   
8. HALL EW, Bradley H, Barker LK, Lewis K, et al
   Estimating hepatitis C prevalence in the United States, 2017-2020.
   Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
   PubMed     Abstract available
   
   
   
9. SEMMLER G, Mandorfer M
   The fade-out of HCV coinfection of people who live with HIV.
   Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
   PubMed    
   
   
   April 2024
10. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
    JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
    PubMed     Abstract available
    
    
    March 2024
11. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
    PubMed     Abstract available
    
    
    
12. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    PubMed     Abstract available
    
    
    
13. KONDILI LA, Craxi A
    Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
    PubMed    
    
    
    February 2024
14. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    PubMed     Abstract available
    
    
    
15. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    PubMed    
    
    
    
16. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    PubMed    
    
    
    January 2024
17. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    PubMed     Abstract available
    
    
    
18. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    PubMed     Abstract available
    
    
    November 2023
19. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    PubMed     Abstract available
    
    
    July 2023
20. MUFTAH AA, Banala C, Raasikh T, Jamali T, et al
    Telehealth interventions in patients with chronic liver diseases: A systematic review.
    Hepatology. 2023;78:179-194.
    PubMed     Abstract available
    
    
    June 2023
21. GOMER A, Klohn M, Jagst M, Nocke M, et al
    Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
    Hepatology. 2023 Jun 20. doi: 10.1097/HEP.0000000000000514.
    PubMed     Abstract available
    
    
    
22. GOUTTENOIRE J, Neyts J
    Towards antivirals against hepatitis E: In the steps of hepatitis C.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000509.
    PubMed    
    
    
    May 2023
23. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
    The national hepatitis c elimination program - AASLD's coalition and call to action.
    Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
    PubMed    
    
    
    April 2023
24. DIETZ J, Lohmann V
    Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
    PubMed    
    
    
    
25. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    PubMed     Abstract available
    
    
    
26. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    PubMed     Abstract available
    
    
    February 2023
27. LUO W, Zhang Y, Zhang T
    Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2023;77:E26-E27.
    PubMed    
    
    
    September 2022
28. ALZUA GP, Pihl AF, Offersgaard A, Velazquez-Moctezuma R, et al
    Identification of novel neutralizing determinants for protection against hepatitis C virus.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772.
    PubMed     Abstract available
    
    
    August 2022
29. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    PubMed     Abstract available
    
    
    
30. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    PubMed     Abstract available
    
    
    July 2022
31. TRUDEAU S, Mendiratta V, Dababneh Y, Hollingsworth J, et al
    Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2022 Jul 27. doi: 10.1002/hep.32688.
    PubMed    
    
    
    
32. SHEHRYAR M, Asif MZ, Umair M
    Letter to the Editor: County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32685.
    PubMed    
    
    
    
33. FUNG S, Choi HSJ, Gehring A, Janssen HLA, et al
    Getting to HBV cure: The promising paths forward.
    Hepatology. 2022;76:233-250.
    PubMed     Abstract available
    
    
    June 2022
34. BARNES E, Cooke GS, Lauer G, Chung RT, et al
    Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.
    Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632.
    PubMed     Abstract available
    
    
    May 2022
35. NEUMANN-HAEFELIN C, Thimme R
    Another important step towards a prophylactic vaccine against hepatitis C.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32557.
    PubMed    
    
    
    April 2022
36. WOLFISBERG R, Thorselius CE, Salinas E, Elrod E, et al
    Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32535.
    PubMed     Abstract available
    
    
    
37. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    PubMed     Abstract available
    
    
    March 2022
38. DONNISON T, McGregor J, Chinnakannan S, Hutchings C, et al
    A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32470.
    PubMed     Abstract available
    
    
    
39. GAVRISHEVA S, Abdurakhmanov D, Milovanova S, Nikulkina E, et al
    Letter to the Editor: High rate of clinical and immunological response in patients with HCV-associated cryoglobulinemia.
    Hepatology. 2022 Mar 8. doi: 10.1002/hep.32425.
    PubMed    
    
    
    
40. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    PubMed     Abstract available
    
    
    February 2022
41. D'AMBROSIO R, Lampertico P
    Is it time to refine HCC surveillance strategies in HCV cured patients?
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.
    PubMed    
    
    
    
42. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
    Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
    PubMed     Abstract available
    
    
    January 2022
43. HUANG CH, Fan JH, Jeng WJ, Chang ST, et al
    Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C.
    Hepatology. 2022 Jan 21. doi: 10.1002/hep.32349.
    PubMed     Abstract available
    
    
    
44. PARK H, Lo-Ciganic WH, Huang J, Wu Y, et al
    Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in Chronic Hepatitis C: An HCV-TARGET Analysis.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32347.
    PubMed     Abstract available
    
    
    
45. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    PubMed     Abstract available
    
    
    
46. JINDAL A
    Oral antivirals in treatment naive chronic hepatitis C infection.
    Hepatology. 2022 Jan 5. doi: 10.1002/hep.32311.
    PubMed    
    
    
    
47. GINES P, Castera L, Lammert F, Graupera I, et al
    Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
    Hepatology. 2022;75:219-228.
    PubMed     Abstract available
    
    
    December 2021
48. KONDILI LA, Monti M, Quaranta MG, Gragnani L, et al
    A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.
    Hepatology. 2021 Dec 16. doi: 10.1002/hep.32281.
    PubMed     Abstract available
    
    
    
49. MURAYAMA A, Ozaki A, Saito H, Sawano T, et al
    Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32262.
    PubMed     Abstract available
    
    
    
50. WYATT B, Perumalswami PV, Mageras A, Miller M, et al
    A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.
    Hepatology. 2021;74:2974-2987.
    PubMed     Abstract available
    
    
    November 2021
51. POLITI J, Guerras JM, Donat M, Belza MJ, et al
    Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
    PubMed     Abstract available
    
    
    
52. ROY A, Dhiman RK
    Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
    Hepatology. 2021;74:2909.
    PubMed    
    
    
    October 2021
53. LAI CW, Nishio A, Hasan S, Kefalakes H, et al
    Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32205.
    PubMed     Abstract available
    
    
    
54. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    PubMed     Abstract available
    
    
    
55. KUSHNER T, Chappell CA
    Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.
    Hepatology. 2021;74:2311-2312.
    PubMed    
    
    
    September 2021
56. TOMLINSON JE, Wolfisberg R, Fahnoe U, Patel RS, et al
    Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.
    Hepatology. 2021;74:1148-1163.
    PubMed     Abstract available
    
    
    August 2021
57. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
    Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
    PubMed     Abstract available
    
    
    July 2021
58. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
    A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
    PubMed     Abstract available
    
    
    
59. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    PubMed     Abstract available
    
    
    June 2021
60. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    PubMed     Abstract available
    
    
    
61. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    PubMed     Abstract available
    
    
    May 2021
62. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
    Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
    PubMed     Abstract available
    
    
    
63. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
    Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
    PubMed     Abstract available
    
    
    April 2021
64. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
    Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
    PubMed     Abstract available
    
    
    March 2021
65. GHANY MG, Lok ASF, Dienstag JL, Feinstone SM, et al
    The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.
    Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830.
    PubMed     Abstract available
    
    
    
66. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    PubMed     Abstract available
    
    
    
67. JHAVERI R, Yee LM, Antala S, Murphy M, et al
    Responsible Inclusion of Pregnant Individuals in Eradicating Hepatitis C Virus.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31825.
    PubMed     Abstract available
    
    
    
68. GRAGNANI L, Lorini S, Marri S, Basile U, et al
    Haematological and genetic markers in the rational approach to HCV SVR patients with or without persisting cryoglobulinemic vasculitis.
    Hepatology. 2021 Mar 15. doi: 10.1002/hep.31804.
    PubMed     Abstract available
    
    
    
69. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available
    
    
    
70. COCHARD J, Bull-Maurer A, Tauber C, Burlaud-Gaillard J, et al
    Differentiated cells in prolonged hypoxia produce highly infectious native-like hepatitis C virus particles.
    Hepatology. 2021 Mar 4. doi: 10.1002/hep.31788.
    PubMed     Abstract available
    
    
    February 2021
71. HALL EW, Schillie S, Vaughan AS, Jones J, et al
    County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31756.
    PubMed     Abstract available
    
    
    
72. ANTUORI A, Montoya V, Pineyro D, Sumoy L, et al
    Characterization of acute HCV infection and transmission networks in people who currently inject drugs in Catalonia: usefulness of dried blood spots.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31757.
    PubMed     Abstract available
    
    
    
73. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    PubMed     Abstract available
    
    
    
74. PARK H, Jiang X, Song HJ, Lo Re V 3rd, et al
    The Impact of Direct-acting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31732.
    PubMed     Abstract available
    
    
    
75. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
    Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
    Hepatology. 2021;73:861-864.
    PubMed    
    
    
    January 2021
76. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available
    
    
    November 2020
77. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    PubMed     Abstract available
    
    
    
78. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available
    
    
    October 2020
79. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available
    
    
    August 2020
80. KAPILA N, Rahman AU, Zervos XB
    Reply.
    Hepatology. 2020;72:788.
    PubMed    
    
    
    
81. TERRAULT NA, Feld JJ
    Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R- Transplants.
    Hepatology. 2020;72:787.
    PubMed    
    
    
    
82. WANGENSTEEN KJ, Chang KM
    Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31481.
    PubMed     Abstract available
    
    
    July 2020
83. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    PubMed     Abstract available
    
    
    
84. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    PubMed     Abstract available
    
    
    April 2020
85. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    PubMed     Abstract available
    
    
    September 2019
86. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
    Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
    PubMed     Abstract available
    
    
    July 2019
87. MANDORFER M, Kozbial K, Schwabl P, Chromy D, et al
    Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy.
    Hepatology. 2019 Jul 31. doi: 10.1002/hep.30885.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.